Drug intelligence / Profile preview

YHR1705 + YHR1706

Development stage: Unknown
Lead developer: Yuhan
Modality: Small Molecules

Overview

YHR1705 + YHR1706 is an investigational combination of two drugs developed by Yuhan Corporation. The combination has been studied in a Phase 1 clinical trial to investigate potential pharmacokinetic drug-drug interactions between the two agents. Both compounds are being evaluated for their effects in metabolic diseases, specifically type 2 diabetes mellitus and dyslipidemia. Detailed mechanisms of action, molecular targets, and individual compound profiles have not been disclosed in public sources as of June 2025.

Beyond the preview

Go deeper on YHR1705 + YHR1706.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHR1705 + YHR1706.

Explore the full profile